Wednesday, September 23, 2026. 12 PM-1 PM ET
Roundtable presenters Dr. David Sacks MB, ChB, FRCPath, Chairman, Steering Committee National Glycohemoglobin Standardization Program (NGSP), and Priya Sivaraman, PhD, Senior Technical Product Manager, Tosoh Bioscience
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Thursday, September 24, 2026 11 AM-12 PM CT
This session explores the evolving role of RAS in precision oncology, from the biology of RAS mutations to the expanding landscape of targeted therapies. Through expert presentations, real-world case discussions, and interactive audience polling, participants will examine best practices for RAS biomarker testing across solid tumors, including lung, colorectal, and pancreatic cancers. The session will highlight practical considerations for tissue and liquid biopsy, strategies to address testing gaps, and the importance of multidisciplinary collaboration to ensure timely identification of patients who may benefit from RAS-targeted therapies.
Webinar presenters David Braxton, MD, Chief of Molecular Pathology Services, Hoag Family Cancer Institute & Hoag Memorial Hospital Presbyterian, and Carlos Becerra, MD, Research Director for Medical Oncology, Margaret Given Larkin Endowed Chair for Developmental Cancer Therapeutics, Hoag Memorial Hospital Presbyterian
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Wednesday, September 30, 2026. 1 PM-1:30 PM ET
Roundtable presenters John Longshore, PhD, Head of Scientific Affairs, Global Oncology Diagnostics, AstraZeneca, and Flora Berisha, MS, Executive Director, Global Head of Diagnostic Partnering and Development, Johnson & Johnson Innovative Medicine, and Mark D. Ewalt, MD, Associate Medical Director for Laboratory Operations, Diagnostic Molecular Pathology, Molecular Diagnostics Service, Department of Pathology and Laboratory Medicine, Memorial Sloan Kettering Cancer Center, and Isabel Preeshagul, DO, MBS, Thoracic Medical Oncologist, Memorial Sloan Kettering Cancer Center
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Thursday, October 1, 2026 1 PM-2 PM ET
This presentation will explore the value of in-house CGP, offer insights into the benefits and drawbacks of incorporation, and provide information about important practical factors when considering in-house implementation of CGP.
Webinar presenter Allison M. Cushman-Vokoun, MD, PhD, FCAP, Medical Director, Molecular Diagnostics and Personalized Medicine Laboratory, Director, Division of Diagnostic Molecular Pathology and Human Genetics, Henry F. Krous Professor of Pathology, University of Nebraska Medical Center
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Tuesday, October 20, 2026 11 AM-12 PM ET
Hear experts review the biological and clinical significance of the HER2 expression continuum in breast tissue, providing a clearer understanding of how these variations might impact diagnosis, and discuss the emerging importance of documenting HER2-low and HER2-ultralow categories using a validated IHC assay.
Webinar presenters Keith Wharton, MD, PhD, Global Medical Affairs Leader–Pathology, Roche Diagnostics Solutions, and Hannah Y. Wen, MD, PhD, Director, Breast Pathology Fellowship, Associate Team Leader, Breast Pathology Team, Attending Pathologist, Memorial Sloan Kettering Cancer Center
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
September 2014—Medical experts representing Vermillion, a multivariate diagnostics company focused on gynecologic cancers and women’s health, presented on Aspira Labs, its new CLIA-certified reference laboratory. Aspira Labs provides expert diagnostic services, including OVA1 and Longitudinal CA 125 testing, which support clinical decision-making and personalized treatment plans.
September 2014—UniConnect announced the release of its PrecisionMDx System for molecular laboratories. The system has been developed for laboratory professionals seeking a focused solution for CAP- and CLIA-certified molecular laboratory operations, and the software platform is ideal for MDx, CDx, and PGx pursuits.
September 2014—Biofortuna announced the expansion of its freeze-dried production service. Biofortuna invested in a new, state-of-the-art freeze-drier and additional climate-control units to meet the increased demands of companies that are outsourcing their freeze-dried production of diagnostic kits. The additional freeze-drier and infrastructure almost doubles the company’s production capacity.
September 2014—Pall Life Sciences’ Acrodisc WBC premium syringe filter is a filtration device designed specifically for use in the capture and recovery of leukocytes and the separation of red blood cells. The Acrodisc WBC filter contains the company’s patented Leukosorb media.
September 2014—Eco-Tek products by Kem-En-Tec, distributed in the U.S. by Rainbow Scientific, reduce the environmental impact of ELISA, blotting, or immunohistochemistry applications by eliminating biological and chemical hazards commonly found in diagnostic assay components, including bovine serum albumin, sodium azide, and harmful organic solvents, without compromising quality, reliability, or stability.
September 2014—Diagnostica Stago celebrated the success of its newest instrument line with the competitive conversion placement of its 100th Compact Max in six months. The Compact Max, an intelligent, user-friendly platform for coagulation testing, is the first of the Max line of instruments that will be rolling out to laboratories worldwide over the next couple of years.
September 2014—The Mix&Go product is a proprietary surface coating for use in diagnostic testing from Anteo Diagnostics. Mix&Go incorporates a type of molecular Velcro that provides a novel approach for attaching fragile proteins to synthetic surfaces distinct to the traditional methods, enabling the development of sensitive and affordable diagnostics.
September 2014—The promises and perils of big data and mobile health were among the hot topics at this year’s meeting of the American Association for Clinical Chemistry.
August 2014—A Proteinase–3 (cANCA) native autoantigen for the in vitro diagnostics market is available from The Binding Site. Expressly designed for use as an integral component in solid-phase, ELISA-based immunoassay test procedures, the Proteinase–3 (cANCA) native autoantigen is for clinical and life-science researchers, medical laboratory professionals, and manufacturers of in vitro diagnostic immunoassay kits and tests for autoimmune conditions.
August 2014—MALDI Biotyper systems can be configured for further functionality by adding new or expanded research-use only software modules or hardware accessories.
The MBT Explorer module provides multiple bioinformatics approaches for spectra comparison, statistical data interpretation, and the generation of customer-specific reference library entries (main spectra) of strains of special interest. Such sub-libraries can be exported and re-imported in networks of collaborating labs.
